（经第五届董事会第十九次会议审议通过） 第一章 总 则 益丰大药房连锁股份有限公司 防范控股股东及关联方占用公司资金制度 第一条 为了建立防止控股股东或实际控制人占用益丰大药房连锁股份有限 公司（以下简称"公司"）资金的长效机制，杜绝控股股东及关联方资金占用行 为的发生，根据《中华人民共和国公司法》 （二）有偿或无偿地拆借公司的资金给控股股东及其他关联方使用； （以下简称"公司法"）、 《上市公司监 管指引第 8 号--上市公司资金往来、对外担保的监管要求》等法律、法规及规范 性文件以及公司章程的有关规定，制定本制度。 第二条 公司董事和高级管理人员对维护公司资金安全有法定义务。 第三条 本制度所称资金占用包括但不限于：经营性资金占用和非经营性资 金占用。经营性资金占用是指控股股东及关联方通过采购、销售等生产经营环节 的关联交易产生的资金占用；非经营性资金占用是指为控股股东及关联方垫付工 资与福利、保险、广告等费用和其他支出、为控股股东及关联方有偿或无偿直接 或间接拆借资金、代偿债务及其他在没有商品和劳务对价情况下提供给控股股东 及关联方使用资金等。 第二章 防范控股股东及关联方的资金占用 第四条 公司应防止 ...

（经第五届董事会第十九次会议审议通过） 第一章 总则 益丰大药房连锁股份有限公司 内幕信息知情人登记、报备和保密制度 第一条 为了进一步规范益丰大药房连锁股份有限公司（以下简称"公司"或 "本公司）)内幕信息管理，加强内幕信息保密工作，维护信息披露公平原则，保 护投资者合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上海证券交易所股票上市规则》《上市公司信息披露管理办法》等相关法律法 规，以及《益丰大药房连锁股份有限公司章程》等文件的规定，并结合本公司实 际情况，制定本制度。 第二章 职能部门及职责分工 第二条 公司董事会是公司内幕信息的管理机构，董事会应当保证内幕信息 管理及内幕信息知情人档案真实、准确和完整，董事长为主要责任人。董事会秘 书为公司内幕信息保密工作负责人，负责办理上市公司内幕信息管理的具体工作 及内幕信息知情人的登记入档事宜。 第三条 公司证券投资部具体实施公司内幕信息的日常管理工作。 第四条 在信息公开披露前，内幕信息知情人应当做好保密工作、配合公司 董事会办公室做好内幕信息知情人登记报备工作。 第五条 董事、高级管理人员及公司各部门、分公司和子公司以及公司能够 对其实施 ...

益丰大药房连锁股份有限公司 重大信息内部报告制度 （经第五届董事会第十九次会议审议通过） 第一章 总则 第一条 为规范益丰大药房连锁股份有限公司（以下简称"公司"）重大信息 内部报告工作，保证公司内部重大信息的快速传递、归集和有效管理，及时、准 确、全面、完整地披露信息，维护公司及投资者的合法权益，根据《中华人民共 和国公司法》、 《中华人民共和国证券法》、 《上市公司信息披露管理办法》、 《上海 证券交易所股票上市规则》 （以下简称" 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公 司股票及其衍生品种交易价格产生较大影响的情形或事件时，按照本制度规定负 有报告义务的有关人员、机构和部门，应及时将有关信息向公司董事长、董事会 秘书报告的制度。 第三条 当公司董事长、董事会秘书需了解重大事项的情况和进展时，相关 部门及人员应予以积极配合和协助，及时、准确、完整地进行回复，并根据要求 提供相关资料。 《上市规则》"）等有关法律、法规及《益 丰大药房连锁股份有限公司章程》 （以下简称"《公司章程》"）、 《益丰大药房连锁 股份有限公司信息披露事务管理制度》的要求，结合公司实际，制定本制度。 第四 ...

Group 1 - The core viewpoint of the article is that Yifeng Pharmacy has decided to extend the completion date of its digitalization project from July 31, 2025, to December 31, 2025, due to the complexity and interconnectivity of the systems involved [5][6]. - The total investment for the digitalization project is 80.642 million yuan, with the company planning to use the same amount from the raised funds [3]. - As of June 30, 2025, the company has invested 73.621 million yuan in the digitalization project, achieving a progress rate of 91.29% [3]. Group 2 - The delay in the project is attributed to the challenges in integrating various systems such as product, logistics, finance, and human resources, which has led to a postponement in platform integration and promotion [4]. - The company has confirmed that the extension will not change the project implementation entity, method, total investment amount, or usage of the raised funds, ensuring that it aligns with the long-term development plan and interests of shareholders [5][6]. - The board of directors and the supervisory board have approved the extension, affirming that the decision complies with relevant laws and regulations [6].

Core Viewpoint - The company intends to use its own funds to pay for part of the investment project and subsequently replace it with raised funds, which is in compliance with regulatory requirements and aims to enhance the efficiency of fund utilization [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds, with net fundraising amounting to approximately 253.43 million yuan after deducting related expenses [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects, including the Jiangsu Phase II, Hubei Pharmaceutical Sorting and Processing Center, and Hebei Pharmaceutical Warehouse, amounts to 253.43 million yuan, with 179.74 million yuan allocated from the raised funds [2]. Reasons for Using Own Funds - The company faces challenges in using raised funds directly for certain expenses, such as employee salaries and social insurance, which must be paid through the basic deposit account. Therefore, it plans to use up to 7.05 million yuan of its own funds for these payments and later replace them with raised funds [3][4]. Impact on the Company - The use of self-funds for project payments and subsequent replacement with raised funds is expected to improve fund utilization efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of the projects [4][5]. Review Procedures and Opinions - The company's board and supervisory committee have approved the proposal to use self-funds for the investment project, confirming that this action does not harm the interests of the company or its shareholders and complies with relevant regulations [5].

Core Viewpoint - Yifeng Pharmacy has extended the completion date of its fundraising project "Yifeng Digital Platform Upgrade Project" from July 31 to December 31, 2023, due to the complexity and challenges in integrating multiple systems [1] Group 1: Project Details - The implementation subject, method, total amount of raised funds, and usage remain unchanged despite the extension of the completion date [1] - The digital project involves integrating various systems including goods, logistics, finance, and human resources, which has led to delays in platform integration and promotion [1] Group 2: Challenges and Risks - The project faces challenges due to the strong interrelation of its components and the difficulty in collaboration, which has contributed to the delay [1] - Some hardware and software systems are deeply integrated with frontline business departments, necessitating thorough testing and feedback to avoid disconnects with actual business operations [1] - Certain remaining funds for personnel salaries, social insurance, and taxes cannot be paid directly from the fundraising account and need to be temporarily covered by the company's own funds, which will later be replaced by the raised funds [1] Group 3: Strategic Adjustments - The company aims to enhance the efficiency of fund usage and reduce investment risks by carefully evaluating the current progress of the fundraising project before deciding on the extension [1]

证券日报网讯 7月30日晚间，益丰药房发布公告称，公司于2025年7月30日召开第五届董事会第十九次 会议和第五届监事会第十三次会议审议通过了《关于使用自有资金支付募投项目部分款项并以募集资金 等额置换的议案》。公司拟在"益丰数字化平台升级项目"实施期间以不超过705.00万元募集资金等额置 换自有资金先行支付的相关支出，该部分等额置换资金视同募投项目使用资金。本次募集资金等额置换 的事项无需提交股东会审议。 （编辑 任世碧） ...

Group 1 - The core point of the article is that Yifeng Pharmacy announced an extension for the completion date of its fundraising investment project, specifically the "Yifeng Digital Platform Upgrade Project," to December 31, 2025 [1] Group 2 - The fifth board meeting and the thirteenth supervisory board meeting were held on July 30, 2025, to review and approve the proposal for the extension of the fundraising investment project [1]

证券日报网讯 7月30日晚间，益丰药房发布公告称，公司第五届监事会第十三次会议审议通过了《关于 取消监事会并修订的议案》等多项议案。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 7月30日晚间，益丰药房发布公告称，公司第五届董事会第十九次会议审议通过了《关于 取消监事会并修订的议案》等多项议案。 ...